Petition to create a publicly owned manufacturer for off-patent, generic drugs in the UK

'Price gouging' describes how pharmaceutical companies exploit the lack of competition in the market to raise the price of medication.

The recent decision by the Competition and Markets Authority (CMA) to fine Advanz Pharma and its private equity partners £100 million for inflating the price of liothyronine (T3) is an example of this.

An endocrinologist from Imperial College, London is calling for the NHS to manufacture essential, off-patent, generic medicines (such as hydrocortisone, liothyronine or insulin) for its own use. This would help bring down the price and make them more widely available.

Please consider signing the petition and sharing it to address this 'price gouging' scandal.

Sign the petition

Read more about price gouging